A Liposome-Based Nanoparticle Vaccine Induces Effective Immunity Against EBV Infection.

ABSTRACT: Background: Epstein-Barr virus (EBV) infects approximately 95% of the global population, causing numerous malignancy-related cases annually and some autoimmune diseases. EBV-encoded gp350, gH, gL, gp42 and gB glycoproteins are identified as antigen candidates for their key role in viral entry, and nanoparticle vaccines displaying them were developed for the advantage of inducing cross-reactive B cell responses. Methods: To develop liposomes displaying nanoparticle vaccine, we synthesized liposomes to present the well-identified EBV-encoded gp350D₁₂₃ glycoprotein on their surface to imitate the viral structure, through the conjugation between N-hydroxysuccinimide (NHS) groups on the liposomes and primary amine of antigens to form stable amide bond. Then we assessed

SUBMITTER: Li P 

PROVIDER: S-EPMC12031204 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature